



IFW #
ANGES-1 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : David L. Vanik
Group Art Unit : 1615
Applicants : Ryuichi Morishita et al.
Application No. : 10/618,362
Confirmation No. : 6703
Filed : July 10, 2003
For : PHARMACEUTICAL COMPOSITION CONTAINING
DECOY AND USE OF THE SAME

~~04/06/2006-WASFAW1 00000053 061075-10618362~~

~~01-FC:1806 180-00-DA~~

New York, New York
March 31, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith is a Supplemental Information Disclosure Statement,
a completed Form PTO/SB/08A and copies of the documents cited therein in the above-
identified application.

This Statement is submitted more than three months from the application
filing date and after the mailing date of the first Office Action on the merits, but before
the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance
under 37 C.F.R. § 1.311. In accordance with 37 C.F.R. § 1.98, this Statement is

accompanied by the fee as set forth in 37 C.F.R. § 1.17(p). The Director is hereby authorized to charge the required fee of \$180.00 to Deposit Account No. 06-1075, Order No. 003734-0051, in payment of the fee for filing a Second Supplemental Information Disclosure Statement.

The Director is hereby authorized to charge payment of any additional fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 003734-0051. A duplicate copy of this Transmittal Letter is enclosed herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Stanley D. Liang (Reg. No. 43,753)

Attorneys for Applicants

Shilpa V. Patent (Reg. No. 57,983)

Agent for Applicants

c/o ISH & NEAVE (Customer No. 1473)

1251 Avenue of the Americas


New York, New York 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

March 31, 2006


Signature of Person



ANGES-1 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : David L. Vanik
Group Art Unit : 1615
Applicants : Ryuichi Morishita et al.
Application No. : 10/618,362
Confirmation No. : 6703
Filed : July 10, 2003
For : PHARMACEUTICAL COMPOSITION CONTAINING
DECOY AND USE OF THE SAME

New York, New York
March 31, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record

the following documents, copies of which are submitted herewith.

04/06/2006 WASFAW1 00000053 10618362

01 FC:1806 180.00 DA

For the Examiner's convenience, applicants have also enclosed a completed Form PTO/SB/08A, listing these documents.

REFERENCES

- Altschul et al., "Basic local alignment search tool," *Journal of Molecular Biology*, 215:403-410 (1990).
- Anderson, "Solution hybridization: RNA:DNA hybridization," *Nucleic Acid Hybridization*, Springer Bios Scientific PublisherS, 4:1:35-47.
- Ardaillou et al., "Production et activite proinflammatoire de necrose tumorale alpha dans le glomerule," *L'Academie Nationale de Medecine*, 179:103-116 (1995).
- Attiga et al., "Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases," *Cancer Research*, 60:4629-4637 (2000).
- Baker et al., "Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging," *British Journal of Surgery*, 87: 1215-1221 (2000).
- Bond et al., "Nuclear factor κ B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts," *Biochemical and Biophysical Research Communications*, 264:561-567 (1999).
- Bond et al., "Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF- κ B," *FEBS Letter*, 435:29-34 (1998).
- Brunner et al., "Single bilayer vesicles prepared without sonication physico-chemical properties," *Biochimica et Biophysica Acta Biomembranes*, 455(2):322-331 (1976).
- Chabaud et al., "Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis," *Cytokine*, 12(7):1092-1099 (2000).
- Deamer, "Preparation and properties of ether-injection liposomes," *Annals of the New York Academy of Sciences*, 308:250-258 (1978).
- Denhardt, "Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy," *Critical Reviews in Oncogenesis*, 7(3&4):261-269 (1996).
- Eberhardt et al., "Amplification of IL-1 β -induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF- κ B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways," *Journal of Immunology*, 165:5788-5797 (2000).
- Farias et al., "Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients," *International Journal of Cancer*, 89:389-394 (2000).
- Gaetani et al., "Metalloproteases and intracranial vascular lesions," *Neurological Research*, 21:385-390 (1999).

- Gish et al., "Identification of protein coding regions by database similarity search," *Nature Genetics*, 3:266-272 (1993).
- Halloran et al., "Pathogenesis of Aneurysms," *Seminars in Vascular Surgery*, 8(2):85-92 (1995).
- Hayashi et al., "Enhanced expression of membrane type-1 matrix metalloproteinase in mesangial proliferative glomerulonephritis," *Journal of the American Society of Nephrology*, 9:2262-2271 (1998).
- Higgins et al., "Using CLUSTAL for multiple sequence alignments," *Methods in Enzymology*, 266:383-402 (1996).
- Holmes et al., "Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat," *Journal of Surgical Research*, 63:305-309 (1996).
- Horikawa et al., "Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma," *Cancer*, 89:715-723 (2000).
- Ikeda et al., "Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film *in situ* zymography," *Clinical Cancer Research*, 6:3290-3296 (2000).
- Jia et al., "Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors," *Angiogenesis: From the Molecular to Integrative Pharmacology*, Edited by Maragoudakis, Kluwer Academic/Plenum Publishers, New York (2000).
- Kanda et al., "The role of the activated form of matrix metalloproteinase-2 in urothelial cancer," *BJU International*, 86:553-557 (2000).
- Katz et al., "Abdominal Aortic Aneurysms," *Seminars in Vascular Surgery*, 8(4):289-298 (1995).
- Kim et al., "Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF- κ B-dependent pathway," *Biochemical and Biophysical Research Communications*, 269:401-405 (2000).
- Kraan et al., "Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis," *Arthritis & Rheumatism*, 43(8):1820-1830 (2000).
- Kuner et al., " β -amyloid binds to p75^{NTR} and activates NF κ B in human neuroblastoma cells," *Journal of Neuroscience Research*, 54:798-804 (1998).
- Lin et al., "Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade," *Biochemical Pharmacology*, 58:911-915 (1999).

Marti, "New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases," *Schweiz Med Wochenschr.*, 130(21):784-788 (2000).

Moore et al., "Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908)," *Journal of Vascular Surgery*, 29:522-532 (1999).

Oda et al., "ETS-1 Converts Endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β_3 ," *Journal of Cellular Physiology*, 178:121-132 (1999).

Origuchi et al., "IL-1-mediated expression of membrane type matrix-metalloproteinase in rheumatoid osteoblasts," *Clinical and Experimental Rheumatology*, 18:333-339 (2000).

Pearson et al., "Improved tools for biological sequence comparison," *PNAS*, 85:2444-2448 (1988).

Pellegrini et al., "Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer," *Cancer Immunology Immunotherapy*, 49:388-394 (2000).

Peters et al., "Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm," *Stroke*, 30:2612-2616 (1999).

Rayet et al., "Aberrant *rel/nfkb* genes and activity in human cancer," *Oncogene*, 18:6938-6947 (1999).

Royds et al., "Response of tumour cells to hypoxia: Role of p53 and NF κ B," *Journal of Clinical Pathology: Molecular Pathology*, 51:55-61 (1998).

Sakata et al., "Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary," *International Journal of Oncology*, 17:673-681 (2000).

Sato et al., "Signal transduction and transcriptional regulation of angiogenesis," *Angiogenesis: From the Molecular to Integrative Pharmacology*, Maragoudakis, Kluwer Academic ed., pp. 109-115, Plenum Publishers (2000).

Segura et al., "Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's Syndrome," *Circulation*, 98:II-331-II-338 (1998).

Shin et al., "Effects of tumor necrosis factor- α and interferon- γ on expression of matrix metalloproteinase-2 and -9 in human bladder cancer cells," *Cancer Letters*, 159:127-134 (2000).

Szoka et al., "Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μm) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes," *Biochimica et Biophysica Acta Biomembranes*, 601(3):559-571 (1980).

Thompson et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," *Nucleic Acids Research*, 22(22):4673-4680 (1994).

Trehanne et al., "Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease," *British Journal of Surgery*, 86:1053-1058 (1999).

Turner et al., "Role of matrix metalloproteinase 9 in pituitary tumor behavior," *Journal of Clinical Endocrinology & Metabolism*, 85(8):2931-2935 (2000).


Yamanaka et al., "Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium," 80(5):677-687 (2000).

Yoshihara et al., "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis," *Annual Rheumatoid Diseases*, 59:455-461 (2000).

Applicants further request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311. In accordance with 37 C.F.R. § 1.98, this Statement is accompanied by the fee as set forth in 37 C.F.R. § 1.17(p).

Respectfully submitted,

A handwritten signature in cursive script, reading "Shilpa V. Patent", is written over a horizontal line.

James F. Haley, Jr. (Reg. No. 27,794)

Stanley D. Liang (Reg. No. 43,753)

Attorneys for Applicants

Shilpa V. Patent (Reg. No. 57,983)

Agent for Applicants

c/o FISH & NEAVE GROUP

ROPES & GRAY LLP


Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known									
				<table border="1"> <tr> <td>Application Number</td> <td>10/618,362</td> </tr> <tr> <td>371(c) Date</td> <td>July 10, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Ryuichi Morishita, et al.</td> </tr> <tr> <td>Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td>David L. Vanik</td> </tr> <tr> <td>Attorney Docket Number</td> <td>ANGES-1 CIP</td> </tr> </table>		Application Number	10/618,362	371(c) Date	July 10, 2003	First Named Inventor	Ryuichi Morishita, et al.	Art Unit	1615
Application Number	10/618,362												
371(c) Date	July 10, 2003												
First Named Inventor	Ryuichi Morishita, et al.												
Art Unit	1615												
Examiner Name	David L. Vanik												
Attorney Docket Number	ANGES-1 CIP												
Sheet	1	of	5										

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ⁶
		Altschul et al., "Basic local alignment search tool," <i>Journal of Molecular Biology</i> , 215:403-410 (1990).	
		Anderson, "Solution hybridization: RNA:DNA hybridization," <i>Nucleic Acid Hybridization</i> , Springer Bios Scientific PublisherS, 4:1:35-47.	
		Ardailou et al., "Production et activite proinflammatoire de necrose tumorale alpha dans le glomerule," <i>L'Academie Nationale de Medecine</i> , 179:103-116 (1995).	
		Attiga et al., "Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases," <i>Cancer Research</i> , 60:4629-4637 (2000).	
		Baker et al., "Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging," <i>British Journal of Surgery</i> , 87: 1215-1221 (2000).	
		Bond et al., "Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts," <i>Biochemical and Biophysical Research Communications</i> , 264:561-567 (1999).	
		Bond et al., "Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB," <i>FEBS Letter</i> , 435:29-34 (1998).	
		Brunner et al., "Single bilayer vesicles prepared without sonication physico-chemical properties," <i>Biochimica et Biophysica Acta Biomembranes</i> , 455(2):322-331 (1976).	
		Chabaud et al., "Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis," <i>Cytokine</i> , 12(7):1092-1099 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/618,362
				371(c) Date	July 10, 2003
				First Named Inventor	Ryuichi Morishita, et al.
				Art Unit	1615
				Examiner Name	David L. Vanik
Sheet	2	of	5	Attorney Docket Number	ANGES-1 CIP

NON PATENT LITERATURE DOCUMENTS			
		Deamer, "Preparation and properties of ether-injection liposomes," <i>Annals of the New York Academy of Sciences</i> , 308:250-258 (1978).	
		Denhardt, "Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy," <i>Critical Reviews in Oncogenesis</i> , 7(3&4):261-269 (1996).	
		Eberhardt et al., "Implication of IL-1 β -induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF- κ B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways," <i>Journal of Immunology</i> , 165:5788-5797 (2000).	
		Farias et al., "Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients," <i>International Journal of Cancer</i> , 89:389-394 (2000).	
		Gaetani et al., "Metalloproteases and intracranial vascular lesions," <i>Neurological Research</i> , 21:385-390 (1999).	
		Gish et al., "Identification of protein coding regions by database similarity search," <i>Nature Genetics</i> , 3:266-272 (1993).	
		Halloran et al., "Pathogenesis of Aneurysms," <i>Seminars in Vascular Surgery</i> , 8(2):85-92 (1995).	
		Hayashi et al., "Enhanced expression of membrane type-1 matrix metalloproteinase in mesangial proliferative glomerulonephritis," <i>Journal of the American Society of Nephrology</i> , 9:2262-2271 (1998).	
		Higgins et al., "Using CLUSTAL for multiple sequence alignments," <i>Methods in Enzymology</i> , 266:383-402 (1996).	
		Holmes et al., "Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat," <i>Journal of Surgical Research</i> , 63:305-309 (1996).	
		Horikawa et al., "Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma," <i>Cancer</i> , 89:715-723 (2000).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/618,362
				371(c) Date	July 10, 2003
				First Named Inventor	Ryuichi Morishita, et al.
				Art Unit	1615
				Examiner Name	David L. Vanik
Sheet	3	of	5	Attorney Docket Number	ANGES-1 CIP

NON PATENT LITERATURE DOCUMENTS			
		Ikeda et al., "Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film <i>in situ</i> zymography," <i>Clinical Cancer Research</i> , 6:3290-3296 (2000).	
		Jia et al., "Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors," <i>Angiogenesis: From the Molecular to Integrative Pharmacology</i> , Edited by Maragoudakis, Kluwer Academic/Plenum Publishers, New York (2000).	
		Kanda et al., "The role of the activated form of matrix metalloproteinase-2 in urothelial cancer," <i>BJU International</i> , 86:553-557 (2000).	
		Katz et al., "Abdominal Aortic Aneurysms," <i>Seminars in Vascular Surgery</i> , 8(4):289-298 (1995).	
		Kim et al., "Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF- κ B-dependent pathway," <i>Biochemical and Biophysical Research Communications</i> , 269:401-405 (2000).	
		Kraan et al., "Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis," <i>Arthritis & Rheumatism</i> , 43(8):1820-1830 (2000).	
		Kuner et al., " β -amyloid binds to p75 ^{NTR} and activates NF κ B in human neuroblastoma cells," <i>Journal of Neuroscience Research</i> , 54:798-804 (1998).	
		Lin et al., "Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade," <i>Biochemical Pharmacology</i> , 58:911-915 (1999).	
		Marti, "New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases," <i>Schweiz Med Wochenschr.</i> , 130(21):784-788 (2000).	
		Moore et al., "Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908)," <i>Journal of Vascular Surgery</i> , 29:522-532 (1999).	
		Oda et al., "ETS-1 Converts Endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β_3 ," <i>Journal of Cellular Physiology</i> , 1789:121-132 (1999).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/618,362
				371(c) Date	July 10, 2003
				First Named Inventor	Ryuichi Morishita, et al.
				Art Unit	1615
				Examiner Name	David L. Vanik
Sheet	4	of	5	Attorney Docket Number	ANGES-1 CIP

NON PATENT LITERATURE DOCUMENTS			
		Origuchi et al., "IL-1-mediated expression of membrane type matrix-metalloproteinase in rheumatoid osteoblasts," <i>Clinical and Experimental Rheumatology</i> , 18:333-339 (2000).	
		Pearson et al., "Improved tools for biological sequence comparison," <i>PNAS</i> , 85:2444-2448 (1988).	
		Pellegrini et al., "Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer," <i>Cancer Immunology Immunotherapy</i> , 49:388-394 (2000).	
		Peters et al., "Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm," <i>Stroke</i> , 30:2612-2616 (1999).	
		Rayet et al., "Aberrant <i>rel/nfkb</i> genes and activity in human cancer," <i>Oncogene</i> , 18:6938-6947 (1999).	
		Royds et al., "Response of tumour cells to hypoxia: Role of p53 and NFκB," <i>Journal of Clinical Pathology: Molecular Pathology</i> , 51:55-61 (1998).	
		Sakata et al., "Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary," <i>International Journal of Oncology</i> , 17:673-681 (2000).	
		Sato et al., "Signal transduction and transcriptional regulation of angiogenesis," <i>Angiogenesis: From the Molecular to Integrative Pharmacology</i> , Maragoudakis, Kluwer Academic ed., pp. 109-115, Plenum Publishers (2000).	
		Segura et al., "Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's Syndrome," <i>Circulation</i> , 98:II-331-II-338 (1998).	
		Shin et al., "Effects of tumor necrosis factor-α and interferon-γ on expression of matrix metalloproteinase-2 and -9 in human bladder cancer cells," <i>Cancer Letters</i> , 159:127-134 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/618,362
				371(c) Date	July 10, 2003
				First Named Inventor	Ryuichi Morishita, et al.
				Art Unit	1615
				Examiner Name	David L. Vanik
Sheet	5	of	5	Attorney Docket Number	ANGES-1 CIP

NON PATENT LITERATURE DOCUMENTS			
		Szoka et al., "Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μ m) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes," <i>Biochimica et Biophysica Acta Biomembranes</i> , 601(3):559-571 (1980).	
		Thompson et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," <i>Nucleic Acids Research</i> , 22(22):4673-4680 (1994).	
		Treharne et al., "Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease," <i>British Journal of Surgery</i> , 86:1053-1058 (1999).	
		Turner et al., "Role of matrix metalloproteinase 9 in pituitary tumor behavior," <i>Journal of Clinical Endocrinology & Metabolism</i> , 85(8):2931-2935 (2000).	
		Yamanaka et al., "Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium," 80(5):677-687 (2000).	
		Yoshihara et al., "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis," <i>Annual Rheumatoid Diseases</i> , 59:455-461 (2000).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**